SonoSite Introduces Next Generation Point-of-Care Ultrasound Product: The EDGE Ultrasound System
18 November 2011 - 12:10PM
Business Wire
SonoSite, Inc. (Nasdaq:SONO), the world leader and
specialist in hand-carried ultrasound for the point-of-care,
announced today that the company has received FDA 510(k) clearance
for its fifth-generation, high-performance EDGE™ ultrasound system.
Designed with physician feedback in mind, the EDGE system reaches a
new level of clinical performance and product design, arming
physicians with a tool to deliver better, safer and improved
patient care. The company is now commencing US customer deliveries.
International deliveries are pending CE marking.
“The EDGE system is a tremendous product and we are excited to
bring it to point-of-care medicine,” said Kevin M. Goodwin,
SonoSite’s President and CEO. “We are encouraged by the timely
regulatory review process, which represents a collaborative effort
by many. We look forward to adding this new tool to our core
markets and providing physicians with the impact they have been
asking for in healthcare delivery.”
“The SonoSite EDGE ultrasound system provides brighter, crisper
images with improved detail,” said Robert Blankenship, MD, FACEP,
Medical Director, St Vincent Medical Center Northeast, Ultrasound
Director, St Vincent Emergency Physicians, Indianapolis. “Anytime
image quality is enhanced, my ability to make
clinical decisions is also improved. It can be hard dealing
with the bright lights and volatile environment of the Emergency
Department; the redesigned black, backlit keyboard, brighter
high-resolution display, and aluminum frame in the EDGE system
are great enhancements. Overall, the EDGE system maintains the
durability that I depend on from SonoSite, while improving the
design and appeal of ultrasound.”
Helping Physicians Improve Patient Care
Designed to help meet the new standards of patient care, the
EDGE system is a perfect diagnostic ultrasound tool for clinical
assessment and procedural guidance at the hospital bedside and in
the physician’s office. The system features new imaging algorithms,
enabling clinicians to clearly visualize images, while reaching
deeper levels of penetration. The EDGE system also boasts a high
luminance LED, high-resolution 12-inch display, which is the
company’s largest monitor to date – making it easier for clinicians
to see the image from across the bed during procedures. The EDGE
introduces a new level of clean-ability with its sealed silicone
keypad – reinforcing SonoSite’s ongoing commitment to assist
medical facilities in the reduction of hospital spread
infections.
The SonoSite Performance and Durability Standard
Dedicated to providing the most robust products, the EDGE
ultrasound system and transducers are the latest products to pass
SonoSite’s rigorous durability standard – the three foot drop test.
With a highly integrated architecture, new titanium shell and
aluminum core, the EDGE system can withstand the harshest and most
demanding clinical environments. Also, the EDGE system weighs less
than 10 pounds and includes our industry leading 5-year
warranty.
At introduction, the EDGE system is available with a complement
of fourteen transducers to support a wide range of examinations and
procedures including thoracic assessment for pathology, vascular
access, needle aspirations and injections, as well as abdominal,
cardiac, nerve, OB/Gyn, musculoskeletal, small parts and vascular
scanning.
About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world
leader in bedside and point-of-care ultrasound and an industry
leader in ultra high-frequency micro-ultrasound technology and
impedance cardiography equipment. Headquartered near Seattle, the
company is represented by ten subsidiaries and a global
distribution network in over 100 countries. SonoSite’s small,
lightweight systems are expanding the use of ultrasound across the
clinical spectrum by cost-effectively bringing high-performance
ultrasound to the point of patient care.
Forward-looking Information and the Private Litigation Reform
Act of 1995
Certain statements in this press release relating to the market
acceptance of our products, possible future sales relating to
expected orders, and our future financial position and operating
results are “forward-looking statements” for the purposes of the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are based on the
opinions and estimates of our management at the time the statements
are made and are subject to risks and uncertainties that could
cause actual results to differ materially from those expected or
implied by the forward-looking statements. These statements are not
guaranties of future performance and are subject to known and
unknown risks and uncertainties and are based on potentially
inaccurate assumptions. Factors that could affect the rate and
extent of market acceptance of our products, the receipt of
expected orders, and our financial performance include our ability
to successfully manufacture, market and sell our ultrasound
systems, our ability to accurately forecast customer demand for our
products, our ability to manufacture and ship our systems in a
timely manner to meet customer demand, variability in quarterly
results caused by the timing of large project orders from
governmental or international entities and the seasonality of
hospital purchasing patterns, timely receipts of regulatory
approvals to market and sell our products, regulatory and
reimbursement changes in various national health care markets,
constraints in government and public health spending, the ability
of our distribution partners and other sales channels such as the
physician office sales force to market and sell our products, the
impact of patent litigation, our ability to execute our acquisition
strategy, the effect of transactions and activities associated with
our issuance of senior convertible debt in July 2007 on the market
price of our common stock, and as well as other factors contained
in the Item 1A. “Risk Factors” section of our most recent Annual
Report on Form 10-K, as updated by our most recent quarterly
reports filed on Form 10-Q filed with the Securities and Exchange
Commission. We caution readers not to place undue reliance upon
these forward-looking statements that speak only as to the date of
this release. We undertake no obligation to publicly revise any
forward-looking statements to reflect new information, events or
circumstances after the date of this release or to reflect the
occurrence of unanticipated events.
iPhone and iPod are trademarks of Apple, Inc., registered in the
US and other countries.
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Jul 2023 to Jul 2024